gileads tamiflu sales up, page-3

Qtr 1 2010 compared to Qtr 1 2009:

"This increase was driven primarily by higher Tamiflu(R) (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $246.3 million in the first quarter of 2010, compared to Tamiflu royalties of $33.2 million in the first quarter of 2009, resulting from increased sales related to influenza pandemic planning initiatives worldwide."

Source: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1415271&highlight=

4th qtr Results:

"The increases were driven primarily by higher Tamiflu(R) (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $194.1 million and $392.7 million in the fourth quarter and full year of 2009, respectively, compared to Tamiflu royalties of $16.0 million and $155.5 million in the fourth quarter and full year of 2008, respectively, resulting from increased sales related to pandemic planning initiatives worldwide."

Source: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1379225&highlight=

Therefore, Qtr 1 2010 compared to Qtr 4 2009:

$246.3 million vs $194.1 million

Interesting, the above is indicating an increase in Qtr 1!


Regards

SP